Corvidia Therapeutics: From Early Stage to Acquisition

Corvidia Therapeutics’ lead candidate ziltivekimab was being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. As the company began preparing for significant financing and clinical milestones, it wanted to leverage these events with key stakeholders.

McDougall Communications developed a comprehensive plan to clearly and concisely convey the company’s business strategy, lead asset and pipeline, disease state focus, and the proven track record of its executive leadership team. Over the course of two years, the team announced Series B financing, the appointment of a new CEO, Phase 2b clinical study results, and clinical society and financial meetings (e.g., American Heart Association and J.P. Morgan Healthcare).

Visibility and company reputation grew substantially, culminating in Corvidia’s acquisition by Novo Nordisk for $725 million USD, with total payments of up to $2.1 billion upon the achievement of regulatory and sales milestones. On the back end of the deal, McDougall Communications worked closely with Novo Nordisk to ensure a smooth transition for the organizations, their investors, employees, and study partners.